Derivation of human embryonic stem cell line MUSIe001-A from an embryo with homozygous α0-thalassemia (SEA deletion)

• Published in: Stem cell research Vol. 43; p. 101695
• Main Authors: Laowtammathron, Chuti, Chingsuwanrote, Pimjai, Choavaratana, Roungsin, Phornwilardsiri, Suphadtra, Sitthirit, Ketsara, Kaewjunun, Chidchanok, Makemaharn, Orawan, Terbto, Papussorn, Waeteekul, Supaporn, Lorthongpanich, Chanchao, U-pratya, Yaowalak, Srisook, Pimonwan, Kheolamai, Pakpoom, Issaragrisil, Surapol
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.03.2020; Elsevier
• ISSN: 1873-5061; 1876-7753
• DOI: 10.1016/j.scr.2019.101695

MUSIe001-A cell line was derived from a Southeast Asian (SEA) type deletion α0-thalassemia embryo. The SEA deletion embryo was donated for research with informed consent. This cell line shows normal hESC morphology, expresses all pluripotent markers, and has the potential to differentiate into all three germ layers in vitro and in vivo. The MUSIe001-A line has normal karyotype and is free from mycoplasma contamination. PCR analysis confirmed the MUSIe001-A cell line to be a SEA type deletion. MUSIe001-A is a valuable proof of principle model for gene therapy that will facilitate the development of new treatments for affected foetuses.